TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) just unveiled an update.
KYORIN Pharmaceutical Co., Ltd. has revised its earnings forecasts for the fiscal year ending March 31, 2025, significantly increasing its expected net sales and profits. This revision is primarily due to a substantial upfront payment from a licensing agreement with Novartis AG for a compound developed in-house, which offsets expenses from another licensing agreement with Bayer AG. The adjustments reflect a positive impact on the company’s financial outlook and strengthen its position in the pharmaceutical market.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company is known for its research and development efforts, particularly in discovering new therapeutic compounds.
YTD Price Performance: 0.09%
Average Trading Volume: 150,719
Technical Sentiment Signal: Buy
Current Market Cap: Yen84.58B
For detailed information about 4569 stock, go to TipRanks’ Stock Analysis page.